Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous or sequential progestin.
ERT is associated with a reduced incidence of coronary risk and cardiac events in postmenopausal women, but increases the risk of endometrial hyperplasia and carcinoma. Combined estrogen and progestin therapy protects the endometrium; however, its effects on heart disease risk factors are not completely known. In our study, 56 ovariectomized New Zealand White rabbits in 7 groups received a 0.5% cholesterol diet for 12 weeks. Controls were not treated with hormones. All other animals received (per kilogram body weight per week) intramuscular injections of either 0.3 mg estrogen (estradiol valerate) alone, 8.3 mg progestin (hydroxyprogesterone caproate) alone, estrogen and progestin continuously in 3 different dosages (0.3 and 8.3 mg; 1 and 8.3 mg; or 1 and 2.8 mg; estrogen and progestin, respectively), or 1 mg estrogen with 25 mg progestin sequentially in 2-week cycles. Eight non-ovariectomized animals served as further controls for endometrial analysis. Morphometric analysis of plaque size in the aortic arch showed that estrogen monotherapy, and the 3 combined therapies with 1 mg estrogen, significantly reduced intimal thickening (P<0.05). The application of progestin alone had no effect on plaque size. The endometrium was enlarged by 3-fold after estrogen treatment, and was decreased by half after progestin treatment, compared with control uteri (P<0.05). In all groups with combined hormone regimens, endometrial size was not significantly different from control uteri. However, these uteri showed more inflammatory reactions, especially when higher doses of hormones were given. In this animal model, doses of progestin that are able to successfully reduce the proliferative effect of estrogen on endometrium do not diminish the desirable antiatherosclerotic properties of estrogen.
Brehme
U
U
Department of Occupational and Social Medicine, University of Tübingen, Germany. ute.brehme@uni-tuebingen.de
Bruck
B
B
Gugel
N
N
Wehrmann
M
M
Hanke
S
S
Finking
G
G
Schmahl
F W
FW
Hanke
H
H
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000821:Animal Feed; D000818:Animals; D001011:Aorta / Q000473:pathology*; D001013:Aorta, Thoracic / Q000473:pathology; D019540:Area Under Curve; D001161:Arteriosclerosis / Q000473:pathology*; D001835:Body Weight; D002784:Cholesterol / Q000008:administration & dosage* / Q000097:blood; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D016889:Endometrial Neoplasms / Q000517:prevention & control; D004717:Endometrium / Q000473:pathology / Q000503:physiopathology*; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D011372:Progestins / Q000627:therapeutic use*; D011817:Rabbits; D014280:Triglycerides / Q000097:blood; D017539:Tunica Intima / Q000473:pathology
D011372:Progestins; D014280:Triglycerides; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone; D002784:Cholesterol